Benign Prostatic Hyperplasia Treatment Market

Home Healthcare And Pharmaceutical Benign Prostatic Hyperplasia Treatment Market

Benign Prostatic Hyperplasia (BPH) Treatment Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Therapy (Mono Drug Therapy, Combination Drug Therapy); By Therapeutic Class (Alpha Blockers, 5-alpha-reductase Inhibitors, Phosphodiesterase-5 Inhibitors); By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Published Date: July 2023
Report ID: BWC22256
Available Format: PDF
Page: 400

Report Overview

Rapidly aging population prone to Benign Prostatic Hyperplasia (BPH) and increasing prevalence of BPH across the world, and advancements in minimally invasive treatment options are projected to propel the expansion of the Global Benign Prostatic Hyperplasia (BPH) Treatment Market during the forecast period between 2023 and 2029.

Global Benign Prostatic Hyperplasia (BPH) Treatment Market - Industry Trends & Forecast Report, 2029

Global benign prostatic hyperplasia (BPH) treatment market size was estimated at USD 5,977.97 million in 2022. During the forecast period between 2023 and 2029, the size of global benign prostatic hyperplasia (BPH) treatment market is projected to grow at a CAGR of 3.13% reaching a value of USD 7,381.99 million by 2029. Major growth drivers for the global benign prostatic hyperplasia (BPH) treatment market include a rising awareness among the general public regarding available treatment options. Technological advancements, such as the introduction of transurethral resection of the prostate (TURP), have also played a significant role in driving market growth. TURP is an endoscopic electrosurgical procedure that involves the removal of a portion of the prostate gland to alleviate blockage caused by abnormal growth. The expanding individual healthcare expenditure capacities and notable improvements in healthcare infrastructure, particularly in developing countries, are expected to further propel the market's expansion. The increasing prevalence of benign prostatic hyperplasia and the associated urological conditions are significant drivers of market growth. Factors such as elevated inflammatory response, sympathetic nerve activity, and oxidative stress contribute to the development of BPH, particularly in obese patients. Hormonal changes in the body are also linked to prostate enlargement and the development of BPH, thereby expanding the market for BPH medications. Also, untapped emerging economies present significant opportunities for market development due to improved healthcare infrastructure, a growing demand for unmet healthcare needs, and increased efforts in research and development (R&D). Hence, such aspects are expected to boost the expansion of global BPH market during the period in analysis.

Benign Prostatic Hyperplasia (BPH) Treatment Market

Global Benign Prostatic Hyperplasia (BPH) Treatment Market – Overview

Benign prostatic hyperplasia (BPH), commonly referred to as the enlargement of the prostate gland, tends to become more prevalent in aging men. An enlarged prostate gland can lead to urinary symptoms, such as urinary retention, and may also affect the bladder, urethra, or kidneys. Treatment options for BPH encompass a range of approaches, including prescription medications, active surveillance, monotherapy and combination therapy, phytotherapy, as well as minimally invasive and invasive surgeries. These procedures often involve the utilization of resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents, and implants. Active surveillance serves as one of the primary treatment methods for BPH. This approach entails closely monitoring the condition without active intervention. Under the guidance of a urologist, regular monitoring of the BPH will take place, typically through annual physical examinations. The focus will be on identifying any new or worsening symptoms before considering further interventions. Additionally, lifestyle modifications, including dietary adjustments and exercise, are commonly recommended to prevent or manage symptoms. Active surveillance is typically suitable for men experiencing mild to moderate symptoms or those who are not significantly bothered by BPH symptoms. However, if symptoms worsen or new ones emerge, the healthcare provider may recommend transitioning to active therapy.

Global Benign Prostatic Hyperplasia (BPH) Treatment Market

Growth Drivers

Growth in Aging World Population Prone to BPH

The market for BPH treatment is projected to be significantly influenced by the aging population, particularly individuals aged 65 and above, who are more susceptible to prostate cancer. As per the World Health Organization's 2021 data, the global population aged 60 and above is projected to nearly double from 12% to 22% between 2015 and 2050. By 2050, approximately 80% of the elderly population will reside in low and middle-income countries. The rate at which the population is aging surpasses previous trends, presenting substantial challenges for healthcare and social systems to adequately address this demographic shift. According to the World Health Organization's May 2020 report, it is estimated that by 2030, one in every six individuals worldwide will be 60 years or older. The number of individuals aged 60 and above is expected to increase from 1 billion in 2020 to 1.4 billion by 2050, while the global population of individuals aged 60 and above is projected to double and reach 2.1 billion by 2050. Moreover, between 2020 and 2050, the number of individuals aged 80 and above is expected to triple, reaching 426 million. BPH is strongly associated with advancing age, with a higher likelihood of occurrence as individuals grow older. Consequently, with the rising geriatric population, the market for BPH treatment is expected to witness robust growth during the forecast period.

Restraints

High Costs associated with BPH Treatment Procedures

The expenses related to diagnosis, medications, surgeries, and follow-up care can be substantial, limiting accessibility to treatment options for many individuals. The cost of BPH medications, such as alpha-blockers and 5-alpha reductase inhibitors, can place a financial burden on patients, particularly for those without adequate insurance coverage. The need for long-term medication use can further escalate the overall expenses for individuals managing BPH. Surgical interventions for BPH, including transurethral resection of the prostate (TURP) and other minimally invasive procedures, are also accompanied by significant costs. These procedures involve specialized equipment, hospitalization, professional fees, and post-operative care, contributing to the overall financial strain on patients. Also, follow-up visits and routine monitoring for BPH management can add to the economic burden. The need for regular check-ups, diagnostic tests, and consultations with healthcare providers can lead to additional costs that may deter some patients from seeking appropriate care. The excessive costs associated with BPH treatment procedures not only affect individuals but also impact healthcare systems and payers. Budgetary constraints and limited resources can result in barriers to accessing advanced treatment options for BPH patients.

Impact of COVID-19 on Global Benign Prostatic Hyperplasia (BPH) Treatment Market

COVID-19 pandemic adversely affected the growth of global benign prostatic hyperplasia (BPH) treatment market. The healthcare system's focus on managing and containing the virus has resulted in a redirection of resources, affecting the diagnosis and treatment of non-emergency conditions such as BPH. Delayed elective surgeries, reduced outpatient visits, and disruptions in the supply chain of medications and medical devices have impacted the market. Moreover, the economic impact of the pandemic has led to financial constraints for individuals, affecting their ability to seek timely BPH treatment. However, with the gradual resumption of healthcare services and the development of vaccination programs, the market recovered in the post-pandemic period, with a renewed emphasis on addressing the unmet needs of BPH patients.

Global Benign Prostatic Hyperplasia (BPH) Treatment Market

Segmental Coverage

Global Benign Prostatic Hyperplasia (BPH) Treatment Market – By Therapy

By therapy, the global benign prostatic hyperplasia (BPH) treatment market is bifurcated into Mono Drug Therapy and Combination Drug Therapy segments. The combination drug therapy segment held a higher market share in the global benign prostatic hyperplasia (BPH) treatment market, due to its enhanced efficacy and comprehensive approach. By combining medications with different mechanisms of action, combination therapy offers improved symptom relief and better outcomes compared to mono drug therapy. The synergistic effects of combined drugs further contribute to its popularity among healthcare providers and patients. Treatment guidelines and recommendations endorsing combination therapy, along with patient preferences for convenience, also drive its market dominance. Streamlining multiple medications into a single combination product enhances medication adherence and patient compliance. These factors collectively contribute to the prominence of combination drug therapy in the BPH treatment market.

Benign Prostatic Hyperplasia (BPH) Treatment Market Share

Global Benign Prostatic Hyperplasia (BPH) Treatment Market – By Therapeutic Class

Based on therapeutic class, the global benign prostatic hyperplasia (BPH) treatment market is divided into Alpha blockers, 5-alpha-reductase inhibitors, and Phosphodiesterase-5 inhibitors segments. The alpha blockers segment holds the highest share in the global benign prostatic hyperplasia (BPH) treatment market for several reasons. The alpha blockers have demonstrated significant efficacy in managing BPH symptoms. These medications work by relaxing the smooth muscles in the prostate and bladder, improving urine flow and alleviating urinary symptoms such as frequent urination, urgency, and incomplete emptying of the bladder. Their ability to provide rapid relief and improve overall quality of life for BPH patients has established them as a preferred treatment option. Also, alpha blockers have a long-standing history of use in BPH treatment and are supported by extensive clinical evidence. They have been extensively studied and proven effective in numerous clinical trials, earning the trust and confidence of healthcare providers. Their established safety profile and well-documented effectiveness make them a reliable choice for both physicians and patients.

Global Benign Prostatic Hyperplasia (BPH) Treatment Market – By Region

The in-depth research report on the global benign prostatic hyperplasia (BPH) treatment market covers various country-specific markets across five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America region holds a dominant position in the market for benign prostatic hyperplasia (BPH) treatment due to its high prevalence of BPH and associated lower urinary tract symptoms. The region's collaboration between hospitals, non-profit organizations, and companies like GlaxoSmithKline has contributed to increased awareness and resources for urological disorder treatment. Additionally, the growing geriatric population in the United States has driven market growth. The demand for early diagnosis and treatment of BPH, as a risk factor for prostate cancer, has created opportunities for market players. Ongoing research and development efforts by major industry players and initiatives to enhance prostate examination and treatment further support market growth in the United States. Thus, the United States is expected to hold a significant share in the BPH treatment market.

Competitive Landscape

Major players operating in the global benign prostatic hyperplasia (BPH) treatment market include Astellas Pharma Inc., Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc., Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Urologix, LLC, Teleflex Incorporated, Olympus Corporation, Merck & Co., Inc., Allergan plc, and Endo International plc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Scope of the Report

Attributes	Details
Years Considered	Historical Data – 2019–2022
	Base Year – 2022
	Estimated Year – 2023
	Forecast Period – 2023–2029
Facts Covered	Revenue in USD Million
Market Coverage	North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Product/ Service Segmentation	Therapy, Therapeutic Class, Region
Key Players	Astellas Pharma Inc., Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc., Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Urologix, LLC, Teleflex Incorporated, Olympus Corporation, Merck & Co., Inc., Allergan plc, Endo International plc

By Therapy

Mono drug therapy
Combination drug therapy

By Therapeutic Class

Alpha blockers
5-alpha-reductase inhibitors
Phosphodiesterase-5 inhibitors

By Region

North America
Europe
Asia Pacific
Latin America
Middle East and Africa

Research Framework
1. Research Objective
2. Product Overview
3. Market Segmentation
Executive Summary
Global Benign Prostatic Hyperplasia (BPH) Treatment Market Insights
1. Industry Value Chain Analysis
2. DROC Analysis
  1. Growth Drivers
    1. Increasing prevalence of BPH globally.
    2. Growing ageing population prone to BPH.
    3. Advancements in minimally invasive treatment options.
  2. Restraints
    1. High costs associated with BPH treatment procedures
    2. Adverse effects and complications associated with certain treatment options
3. Opportunities
  1. 1. Development of novel and more effective treatment options.
    2. Increasing investment in research and development.
  2. Challenges
    1. Intense competition among market players.
    2. Slow adoption of advanced treatment technologies in certain regions.
4. Technology Advancements/Recent Developments
5. Regulatory Framework
6. Porter’s Five Forces Analysis
  1. Bargaining Power of Suppliers
  2. Bargaining Power of Buyers
  3. Threat of New Entrants
  4. Threat of Substitutes
  5. Intensity of Rivalry
Global Benign Prostatic Hyperplasia (BPH) Treatment Market Overview
1. Market Size & Forecast, 2019–2029
  1. By Value (USD Million)
2. Market Share and Forecast
  1. By Therapy
    1. Mono drug therapy
    2. Combination drug therapy
  2. By Therapeutic Class
    1. Alpha blockers
    2. 5- alpha-reductase inhibitors
    3. Phosphodiesterase-5 inhibitors
    4. Others
  3. By Region
    1. North America
    2. Europe
    3. Asia Pacific (APAC)
    4. Latin America (LATAM)
    5. Middle East and Africa (MEA)
North America Benign Prostatic Hyperplasia (BPH) Treatment Market
1. Market Size & Forecast, 2019–2029
  1. By Value (USD Million)
2. Market Share & Forecast
  1. By Therapy
  2. By Therapeutic Class
  3. By Country
    1. United States
      1. By Therapy
      2. By Therapeutic Class
    2. Canada
      1. By Therapy
      2. By Therapeutic Class
Europe Benign Prostatic Hyperplasia (BPH) Treatment Market
1. Market Size & Forecast, 2019–2029
  1. By Value (USD Million)
2. Market Share & Forecast
  1. By Therapy
  2. By Therapeutic Class
  3. By Country
    1. Germany
      1. By Therapy
      2. By Therapeutic Class
    2. United Kingdom
      1. By Therapy
      2. By Therapeutic Class
    3. Italy
      1. By Therapy
      2. By Therapeutic Class
    4. France
      1. By Therapy
      2. By Therapeutic Class
    5. Spain
      1. By Therapy
      2. By Therapeutic Class
    6. Belgium
      1. By Therapy
      2. By Therapeutic Class
    7. Russia
      1. By Therapy
      2. By Therapeutic Class
    8. The Netherlands
      1. By Therapy
      2. By Therapeutic Class
    9. Rest of Europe
      1. By Therapy
      2. By Therapeutic Class
Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market
1. Market Size & Forecast, 2019–2029
  1. By Value (USD Million)
2. Market Share & Forecast
  1. By Therapy
  2. By Therapeutic Class
  3. By Country
    1. China
      1. By Therapy
      2. By Therapeutic Class
    2. India
      1. By Therapy
      2. By Therapeutic Class
    3. Japan
      1. By Therapy
      2. By Therapeutic Class
    4. South Korea
      1. By Therapy
      2. By Therapeutic Class
    5. Australia & New Zealand
      1. By Therapy
      2. By Therapeutic Class
    6. Indonesia
      1. By Therapy
      2. By Therapeutic Class
    7. Malaysia
      1. By Therapy
      2. By Therapeutic Class
    8. Singapore
      1. By Therapy
      2. By Therapeutic Class
    9. Vietnam
      1. By Therapy
      2. By Therapeutic Class
    10. Rest of APAC
      1. By Therapy
      2. By Therapeutic Class
Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market
1. Market Size & Forecast, 2019–2029
  1. By Value (USD Million)
2. Market Share & Forecast
  1. By Therapy
  2. By Therapeutic Class
  3. By Country
    1. Brazil
      1. By Therapy
      2. By Therapeutic Class
    2. Mexico
      1. By Therapy
      2. By Therapeutic Class
    3. Argentina
      1. By Therapy
      2. By Therapeutic Class
    4. Peru
      1. By Therapy
      2. By Therapeutic Class
    5. Rest of LATAM
      1. By Therapy
      2. By Therapeutic Class
Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market
1. Market Size & Forecast, 2019–2029
  1. By Value (USD Million)
2. Market Share & Forecast
  1. By Therapy
  2. By Therapeutic Class
  3. By Country
    1. Saudi Arabia
      1. By Therapy
      2. By Therapeutic Class
    2. UAE
      1. By Therapy
      2. By Therapeutic Class
    3. Qatar
      1. By Therapy
      2. By Therapeutic Class
    4. Kuwait
      1. By Therapy
      2. By Therapeutic Class
    5. South Africa
      1. By Therapy
      2. By Therapeutic Class
    6. Nigeria
      1. By Therapy
      2. By Therapeutic Class
    7. Algeria
      1. By Therapy
      2. By Therapeutic Class
    8. Rest of MEA
      1. By Therapy
      2. By Therapeutic Class
Competitive Landscape
1. List of Key Players and Their Offerings
2. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share Analysis, 2022
3. Competitive Benchmarking, By Operating Parameters
4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
Impact of Covid-19 on Global Benign Prostatic Hyperplasia (BPH) Treatment Market
Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
1. Astellas Pharma Inc.
2. Eli Lilly and Company
3. GlaxoSmithKline plc
4. AstraZeneca plc
5. Johnson & Johnson
6. Pfizer Inc.
7. Abbott Laboratories
8. Boston Scientific Corporation
9. Medtronic plc
10. Urologix, LLC
11. Teleflex Incorporated
12. Olympus Corporation
13. Merck & Co., Inc.
14. Allergan plc
15. Endo International plc
16. Other Prominent Players
Key Strategic Recommendations
Research Methodology
1. Qualitative Research
  1. Primary & Secondary Research
2. Quantitative Research
3. Market Breakdown & Data Triangulation
  1. Secondary Research
  2. Primary Research
4. Breakdown of Primary Research Respondents, By Region
5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

Figures

Figure 1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Segmentation

Figure 2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Value Chain Analysis

Figure 3 Company Market Share Analysis, 2022

Figure 4 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 5 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 6 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 7 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Region, By Value, 2019−2029

Figure 8 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 9 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 10 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 11 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Country, By Value, 2019−2029

Figure 12 United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 13 United States Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 14 United States Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 15 Canada Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 16 Canada Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 17 Canada Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 18 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 19 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 20 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 21 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Country, By Value, 2019−2029

Figure 22 Germany Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 23 Germany Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 24 Germany Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 25 United Kingdom Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 26 United Kingdom Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 27 United Kingdom Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 28 Italy Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 29 Italy Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 30 Italy Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 31 France Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 32 France Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 33 France Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 34 Spain Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 35 Spain Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 36 Spain Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 37 The Netherlands Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 38 The Netherlands Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 39 The Netherlands Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 40 Belgium Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 41 Belgium Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 42 Belgium Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 43 NORDIC Countries Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 44 NORDIC Countries Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 45 NORDIC Countries Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 46 Rest of Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 47 Rest of Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Technology, By Value, 2019−2029

Figure 48 Rest of Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 49 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 50 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 51 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Deployment, By Value, 2019−2029

Figure 52 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Country, By Value, 2019−2029

Figure 53 China Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 54 China Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 55 China Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 56 India Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 57 India Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 58 India Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 59 Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 60 Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 61 Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 62 South Korea Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 63 South Korea Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 64 South Korea Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 65 Australia & New Zealand Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 66 Australia & New Zealand Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 67 Australia & New Zealand Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 68 Indonesia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 69 Indonesia Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 70 Indonesia Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 71 Malaysia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 72 Malaysia Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 73 Malaysia Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 74 Singapore Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 75 Singapore Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 76 Singapore Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 77 Philippines Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 78 Philippines Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 79 Philippines Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 80 Vietnam Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 81 Vietnam Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 82 Vietnam Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 83 Rest of APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 84 Rest of APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 85 Rest of APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 86 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 87 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 88 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 89 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Country, By Value, 2019−2029

Figure 90 Brazil Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 91 Brazil Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 92 Brazil Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 93 Mexico Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 94 Mexico Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 95 Mexico Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 96 Argentina Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 97 Argentina Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 98 Argentina Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 99 Peru Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 100 Peru Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 101 Peru Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 102 Colombia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 103 Colombia Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 104 Colombia Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 105 Rest of LATAM Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 106 Rest of LATAM Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 107 Rest of LATAM Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 108 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 109 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 110 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 111 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Country, By Value, 2019−2029

Figure 112 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 113 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 114 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 115 UAE Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 116 UAE Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 117 UAE Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 118 Qatar Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 119 Qatar Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 120 Qatar Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 121 Kuwait Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 122 Kuwait Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 123 Kuwait Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 124 Iran Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 125 Iran Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 126 Iran Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 127 South Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 128 South Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 129 South Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 130 Nigeria Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 131 Nigeria Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 132 Nigeria Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 133 Kenya Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 134 Kenya Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 135 Kenya Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 136 Egypt Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 137 Egypt Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 138 Egypt Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 139 Morocco Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 140 Morocco Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 141 Morocco Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 142 Algeria Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 143 Algeria Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 144 Algeria Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

Figure 145 Rest of MEA Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029

Figure 146 Rest of MEA Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029

Figure 147 Rest of MEA Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

List of Tables

Table 1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 3 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Region, By Value, 2019−2029

Table 4 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 5 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 6 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Country, By Value, 2019−2029

Table 7 United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 8 United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 9 Canada Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 10 Canada Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 11 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 12 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 13 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Country, By Value, 2019−2029

Table 14 Germany Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 15 Germany Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 16 United Kingdom Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 17 United Kingdom Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 18 Italy Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 19 Italy Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 20 France Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 21 France Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 22 Spain Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 23 Spain Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 24 The Netherlands Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 25 The Netherlands Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 26 Belgium Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 27 Belgium Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 28 NORDIC Countries Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 29 NORDIC Countries Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 30 Rest of Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 31 Rest of Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 32 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 33 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 34 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Country, By Value, 2019−2029

Table 35 China Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 36 China Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 37 India Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 38 India Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 39 Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 40 Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 41 South Korea Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 42 South Korea Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 43 Australia & New Zealand Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 44 Australia & New Zealand Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 45 Indonesia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 46 Indonesia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 47 Malaysia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 48 Malaysia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 49 Singapore Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 50 Singapore Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 51 Philippines Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 52 Philippines Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 53 Vietnam Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 54 Vietnam Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 55 Rest of APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 56 Rest of APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 57 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 58 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 59 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Country, By Value, 2019−2029

Table 60 Brazil Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 61 Brazil Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 62 Mexico Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 63 Mexico Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 64 Argentina Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 65 Argentina Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 66 Peru Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 67 Peru Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 68 Colombia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 69 Colombia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 70 Rest of LATAM Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 71 Rest of LATAM Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 72 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 73 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Country, By Value, 2019−2029

Table 74 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 75 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 76 UAE Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 77 UAE Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 78 Qatar Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 79 Qatar Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 80 Kuwait Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 81 Kuwait Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 82 Iran Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 83 Iran Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 84 South Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 85 South Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 86 Nigeria Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 87 Nigeria Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 88 Kenya Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 89 Kenya Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 90 Egypt Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 91 Egypt Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 92 Morocco Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 93 Morocco Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 94 Algeria Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 95 Algeria Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 96 Rest of MEA Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 97 Rest of MEA Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 98 Astellas Pharma Inc. Company Overview

Table 99 Astellas Pharma Inc. Financial Overview

Table 100 Eli Lilly and Company Overview

Table 101 Eli Lilly and Company Financial Overview

Table 102 GlaxoSmithKline plc Company Overview

Table 103 GlaxoSmithKline plc Financial Overview

Table 104 AstraZeneca plc Company Overview

Table 105 AstraZeneca plc Financial Overview

Table 106 Johnson & Johnson Company Overview

Table 107 Johnson & Johnson Financial Overview

Table 108 Pfizer Inc. Company Overview

Table 109 Pfizer Inc. Financial Overview

Table 110 Abbott Laboratories Company Overview

Table 111 Abbott Laboratories Financial Overview

Table 112 Boston Scientific Corporation Company Overview

Table 113 Boston Scientific Corporation Financial Overview

Table 114 Medtronic plc Company Overview

Table 115 Medtronic plc Financial Overview

Table 116 Urologix, LLC Company Overview

Table 117 Urologix, LLC Financial Overview

Table 118 Teleflex Incorporated Company Overview

Table 119 Teleflex Incorporated Financial Overview

Table 120 Endo International plc Company Overview

Table 121 Endo International plc Financial Overview

Table 122 Other Prominent Players Company Overview

Table 123 Other Prominent Players Financial Overview

Market Segmentation

No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

This website is secure and your personal details are safe.

Frequently Asked Questions (FAQs):

1. Which is the leading therapeutic class segment in the Global Benign Prostatic Hyperplasia (BPH) Treatment Market?

Ans: The alpha blockers segment is expected to hold the highest market share in the Global Benign Prostatic Hyperplasia (BPH) Treatment Market by therapeutic class.

2. What are the major factors driving the growth of Global Benign Prostatic Hyperplasia (BPH) Treatment Market?

Ans: Major factors driving the growth of the Global Benign Prostatic Hyperplasia (BPH) Treatment Market include increasing prevalence of BPH globally, growing ageing population prone to BPH, and advancements in minimally invasive treatment options.

3. What is the current market size of Global Benign Prostatic Hyperplasia (BPH) Treatment Market?

Ans: Global Benign Prostatic Hyperplasia (BPH) Treatment Market size was estimated at USD 5,977.97 million in 2022.

4. Which segment accounts for a higher market share in the Global Benign Prostatic Hyperplasia (BPH) Treatment Market by therapy?

Ans: The combination drug therapy segment is expected to hold a higher market share in the Global Benign Prostatic Hyperplasia (BPH) Treatment Market by therapy.

5. Name the key players in Global Benign Prostatic Hyperplasia (BPH) Treatment Market.

Ans: Key players in the Global Benign Prostatic Hyperplasia (BPH) Treatment Market include Astellas Pharma Inc., Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc., Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Urologix, LLC, Teleflex Incorporated, Olympus Corporation, Merck & Co., Inc., Allergan plc, and Endo International plc.

PLACE AN ORDER

SINGLE USER LICENSE
$ 4850
GROUP LICENSE
$ 5750
ENTERPRISE LICENSE
$ 8150
EXCEL DATA PACK
$ 3250

Request for Sample

RELATED REPORTS

WHY CHOOSE US

24/7 Research Support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Custom Research Service

Ask the Analyst to customize an exclusive study to serve your research needs
Quality & Accuracy

Ask the Analyst to customize an exclusive study to serve your research needs
Data Visualization

As the business world is changing dynamically every day. We need to stay pin point in relation to data management and optimum data utilization
Information security

We never share your personal and confidential information. Your personal information is safe and secure with us.